All News

Compounded with lifestyle interventions, researchers compared liraglutide with a placebo to measure its efficacy amongst children under 12 years old.

Following the Federal Trade Commission’s interim report on PBMs, legislators are galvanized to make change happen.

The Eversense 365 is the world’s first long-term CGM that provides 1 year of use and should be available by the fourth quarter of 2024.

The health care giant’s pharmacy benefit manager subsidiary filed a lawsuit claiming that the FTC’s recent 6(b) report was false and misleading.

The approval was based on data from the phase 3 MANDARA trial, where the therapy met the primary endpoint of proportion of patients in remission at weeks 36 and 48.

A co-administration option for both vaccinations can increase the likelihood of older adults completing the vaccination series and improve health outcomes for the patient population.

The MVA-BN vaccine is manufactured by Bavarian Nordic and has shown strong efficacy against mpox infection in real-world studies.

In an installment of Drug Topics’ 5 Questions With a Pharmacist, Michael and Joan Kim of Grubb’s Pharmacy in Washington, DC, discussed their practice and the community it serves.

The CDC recently released a report detailing 2023 statistics regarding adult obesity within the 50 US states.

Mark Garofoli combined personal anecdotes with professional expertise to deliver a compelling presentation on kidney stone pain at this year’s PAINWeek National Conference.

Patients who completed electronic patient-reported outcome measures said they made them feel more involved in their care and better supported.

Learn how one pharmacy chain adopted a cash pricing solution that offered new opportunities for profitability while still offering competitive pricing to customers.

Lebrikizumab-lbks is a targeted treatment that addresses the root cause of atopic dermatitis; by reducing inflammation throughout the body, it can help alleviate the dry, itchy, and irritated skin that often characterizes the condition.

Albert Dahan, MD, PhD, discusses recent data on Tris Pharma’s first-in-class dual-NMR agonist and how it will fit into the broader landscape of pain management therapies.

In case you missed it, this week we had news about novel treatments for dry eye disease, art therapy and mental health, abdominal fat's role in pain, and more.

Researchers analyzed the outcomes of positive airway pressure therapy for Medicare beneficiaries with obstructive sleep apnea.

Gilead said data from the study will support global regulatory filings that the company plans to begin by the end of the year.

Researchers conducted a meta-analysis detailing previous patient outcomes in response to visual art therapy interventions.

Over 30 million American adults experience some hearing loss, yet only one-fifth benefit from hearing aids; the FDA’s approval will expand access to the technology for the patient population.

Check out important updates from the FDA for the week of August 9.

Findings could inform future clinical practices on the treatment of DED for the more than 400 million people worldwide with the condition.

Industry experts and physicians conducted a state-by-state breakdown of vaccination statistics for children and teenagers as well as adults and elderly individuals.

Two phase 3 trials demonstrated that once-weekly insulin efsitora is as effective as daily insulin in lowering HbA1c in both type 1 (T1D) and type 2 diabetes (T2D).

A recent meta-analysis found that supplementing with vitamin D could improve blood pressure, blood lipid levels, and glycemic parameters.

To further understand PBM market concentration, researchers separately analyzed commercial insurance, Medicare Part D, and Medicaid managed care market strategies of the 3 biggest PBMs.

“Reducing abdominal adiposity may be considered a target for chronic pain management, particularly in those with pain in multiple sites and widespread pain,” wrote investigators.

Researchers looked for a better understanding of medical debt and what type of role the US government plays in lessening the burden on patients and their health care costs.

Viridian Therapeutics also said it has completed enrollment for a second phase 3 trial of veligrotug, THRIVE-2, and expects topline data to be available by the end of this year.